Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis

Kwang Sik Kim, Jane H. Kang, Arnold S. Bayer

Research output: Contribution to journalArticle


We evaluated the activity of teicoplanin against a type-ill group B streptococcal strain in vitro and in vivo and compared the results with those of penicillin G. In vitro, the minimal inhibitory and minimal bactericidal concentrations of teicoplanin were 2- to 4-fold greater than those of penicillin G. In vivo studies were carried out with an experimental bacteremia and meningitis model in newborn rats. Eighty-one infected animals were randomized to receive teicoplanin 5, 10 or 20 mg/kg, twice daily, or penicillin G 50 or 200 mg/kg, twice daily, or saline (0.05 ml), twice daily. The mean serum levels of teicoplanin were maintained above 100x the minimal bactericidal concentration for 7-8 h even with a dose of 5 mg/kg. The mean penetration of teicoplanin into the cerebrospinal fluid was estimated as 2.4-8.2% of those of concomitant levels in serum. The overall efficacy of teicoplanin was similar to that of penicillin G as judged by mortality rates. However, two bacteremic animals which were free of meningitis at the beginning of therapy developed this complication during 4 days of teicoplanin therapy, in contrast with none in the penicillin group. Further studies are needed to understand the reason(s) for these failures with teicoplanin therapy.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
Issue number3
StatePublished - 1987
Externally publishedYes


  • Bacteremia
  • Group B Streptococci
  • In vitro/in vivo studies
  • Meningitis
  • Penicillin G
  • Teicoplanin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis'. Together they form a unique fingerprint.

  • Cite this